{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"23.4","value":"11.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"The analysis of 100-day mortality after allogeneic HSCT was assessed for all participants who received an allogeneic HSCT while in remission (CR/CRh\\*) following treatment with blinatumomab. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT.\n\nPatients alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.\n\nThe 100-day mortality rate after allogeneic HSCT was defined as the percentage of patients having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Participants who received an allogeneic HSCT while in remission induced by blinatumomab treatment.","reportingStatus":"POSTED","timeFrame":"From the date of allogeneic HSCT until the data cut-off date of 10 October 2013; median observation time was 7.4 months.","title":"100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant","type":"SECONDARY","unitOfMeasure":"percentage of participants"}